Specific oncogenic mutations in the Toll/IL-1 receptor (TIR) domain of MyD88 are found in 91% of lymphoplasmacytic lymphomas [43], 29% of ABC DLBCL, 9% of gastric MALT lymphomas [42], 13% of splenic marginal zone lymphomas (SMZL) [44], 2.9% of CLL cases and 5.6% of IgH-mutated CLL cases [45]. Here, MYD88 is linked to diffuse large B-cell lymphoma.